Survival of Patients With Idiopathic Pulmonary Arterial Hypertension After Listing for Transplantation: Impact of Iloprost and Bosentan Treatment

Journal of Heart and Lung Transplantation

Volumn 26, Issue 9, 2007, Pages 898-906

  Dandel, Michael ^a   Lehmkuhl, Hans B ^a   Mulahasanovic, Sead ^a   Weng, Yuguo ^a   Kemper, Dagmar ^a   Grauhan, Onnen ^a   Knosalla, Christoph ^a   Hetzer, Roland ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ADULT; ARTICLE; CONTINUOUS INFUSION; DRUG DOSE INCREASE; FEMALE; HEART FAILURE; HUMAN; IDIOPATHIC DISEASE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT DISEASE; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HEART-LUNG TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECEPTORS, ENDOTHELIN; SULFONAMIDES; VASODILATOR AGENTS; WAITING LISTS;

EID: 34548436137     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.07.012     Document Type: Article

References (30)

1. D'Alonzo G., Bart R., Ayres S., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
2. Barst R., Rubin L., Long W., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
3. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl (2004) 48S-55S
4. McLaughlin V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension. Chest 126 suppl (2004) 78S-92S
5. Galie N., Seeger W., Naeije R., et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl (2004) 81S-88S
6. Girgis R.E., Mahai S.C., Krishnan J.A., et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with scleroderma spectrum of disease. J Heart Lung Transplant 24 (2005) 626-631
7. Simpson C.M., Penny D.J., Cochrane A.D., et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 25 (2006) 469-473
8. Charman S.C., Sharples L.D., McNeil K.D., and Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 21 (2002) 226-232
9. De Meester J., Smits J.M.A., Persijn G.G., et al. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 21 (2002) 226-232
10. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
11. Galie N., Manus A., and Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2 (2003) 123-137
12. Olschewski H., Walmrath D., Schermuly R., et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124 (1996) 820-824
13. Higenbottam T.W., Butt A.Y., Dinh-Xaun A.T., et al. Treatment of pulmonary hypertension with continuous infusion of a prostacyclin analog, iloprost. Heart 79 (1998) 175-179
14. Hoeper M.M., Olschewski H.A., Ghofrani H.A., et al. A comparison of the acute hemo-dynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 5 (2000) 176-182
15. Olschewski H.A., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
16. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Resprir Crit Care Med 160 (1999) 600-607
17. Dandel M., and Hetzer R. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension. Curr Vasc Pharmacol 1 (2003) 171-181
18. Ewert R., Wensel C., Opitz C., et al. Prognosis in patients with primary pulmonary hypertension: awaiting lung transplantation. Transplant Proc 33 (2001) 3574-3575
19. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
20. Sitbon O., Badesch D.B., Cannik R.N., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1 year follow up. Chest 124 (2003) 247-254
21. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
22. McLaughlin V., Genthner D., Panella M.M., and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 773-774
23. Hoeper M.M., Leuchte H., Halank L., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 (2006) 691-694
24. Nathan S.D. Lung transplantation: disease specific considerations for referral. Chest 127 (2005) 1006-1016
25. Doyle R.L., McCrory D., Channick R.N., et al. Surgical treatments/interventions for pulmonary arterial hypertension. ACCP Evidence-based clinical practice guidelines. Chest 126 suppl (2004) 63S-71S
26. Trulock E.P., Edwards L.B., Taylor O.D., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956-967
27. Trulock E.P. Lung transplantation: outcomes. In: Norman D.J., and Turka L.A. (Eds). Primer on transplantation (2001), American Society of Transplantation, Mt Laurel, NJ 716-720
28. McLaughlin V.V., Shilington A., and Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
29. De Meester J., Smits J.M.A., Persijn G.G., et al. Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration. J Heart Lung Transplant 18 (1999) 563-571
30. McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 36 suppl 3 (2006) 10-15